Chen, Mengdie
Zhu, Anying
Zhu, Furong
Lei, Ziwen
Huang, Tao
Du, Shengnan
Wang, Dongdong
Zhang, Xiaoyu
Min, Huan
Qi, Yingqiu
Nie, Guangjun
Article History
Received: 25 August 2023
Revised: 13 October 2023
Accepted: 13 October 2023
First Online: 17 November 2023
Conflicts of interest
: Yingqiu Qi, Mengdie Chen, and Huan Min et al. have filed a patent application based on this work. In accordance with the Zhengzhou University procedures and our ethical obligations as researchers, we report that ET is named on patents that describe the targeting peptide exhibited a binding affinity to LRG1. Cy5-ET is also named on patents describing the probe of tumor targeting, and application for peptide drug conjugate and tumor therapy. We have disclosed those interests fully to the University of Zhengzhou, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. The remaining authors declare no competing interests.